Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +42.01%
#2 0G 0G +31.99%
#3 Fake World Assets Fake World Assets +21.86%
#4 Zora Zora +18.19%
#5 Full Moon Full Moon +17.70%
#6 SAFEcoin SAFEcoin +17.57%
#7 Nockchain Nockchain +15.63%
#8 ADO Protocol ADO Protocol +15.62%
#9 Axelar Axelar +13.79%
#10 Notcoin Notcoin +12.84%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Classement en actions #13173
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Prix de l'action
$8.46
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$514.33M
Changement (1 jour)
-2.08%
Changement (1 an)
128.03%
Pays
US
Échange Kyverna Therapeutics, Inc. (KYTX)

Catégorie

Healthcare
Ratio P/B pour Kyverna Therapeutics, Inc. (KYTX)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Kyverna Therapeutics, Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Kyverna Therapeutics, Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH